Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with invasive breast cancer confirmed by laboratory testing of tissue samples
- People who have a measurable area of cancer in the breast (the longest measurement must be at least 2.5 cm) after an initial diagnostic biopsy
- People who have not previously had chemotherapy or radiation therapy to the affected breast for this cancer (prior bone-strengthening bisphosphonate therapy is allowed)
- People aged 18 years or older
- People whose general health and ability to carry out daily activities meets a level rated 0 or 1 on a standard medical scale (confirm with trial site)
- People who are willing to have a core biopsy taken from the breast tumour to measure certain biological markers before treatment begins
- People who are not pregnant and not breastfeeding
- People who do not have any metallic implants in their body that are not compatible with an MRI machine
- People who are able to understand and are willing to sign the required consent forms for this trial
- People whose cancer is classified as Stage II or III, or a specific advanced stage affecting only the lymph nodes above the collarbone, or inflammatory breast cancer meeting the trial's staging criteria (confirm with trial site)
- People whose tumour has any level of hormone receptor status (ER/PgR) and any HER-2 status, as long as the tumour meets the specific testing profile described in the trial protocol (confirm with trial site)
- People whose blood and organ function results fall within the required ranges, including adequate white blood cell counts, platelet levels, liver function, and kidney function (confirm with trial site)
- People who do not have severe or uncontrolled heart disease, and whose heart pumping function is at least 50% as measured by imaging
- People who have no signs of cancer that has spread to distant parts of the body, confirmed by chest X-ray, bone scan, and blood tests
- People whose tumour meets one of the specific testing profiles using a tool called MammaPrint, combined with hormone receptor and HER2 results (confirm with trial site)
Who may not be able to join:
- People who have taken part in another experimental drug trial within the 30 days before starting this study
- People who have had a serious allergic reaction to medicines that are chemically or biologically similar to the treatments used in this trial
- People who have other serious, uncontrolled illnesses such as an active infection, heart failure, unstable chest pain, irregular heart rhythms, or mental health or personal circumstances that would make it difficult to follow the trial's requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Laura Esserman, MD, MBA, University of California, San Francisco
Phone: (855) 866-0505
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine whether adding experimental agents to standard neoadjuvant medications increases the probability of pathologic complete response (pCR) over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.